Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325767 · ClinicalTrials.gov registry record · Phase 4
Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00325767: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT00325767 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00325767, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.
Interventions
- DRUG nebulized albuterol (2.5 mg/3ml/dose)
- DRUG nebulized levalbuterol (1.25 mg/3ml/dose)
- DRUG nebulized placebo (3ml/dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325767
The ClinicalTrials.gov registry entry for NCT00325767 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nebulized albuterol (2.5 mg/3ml/dose) is the first listed.
NCT00325767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325767 about?
NCT00325767 is a clinical study titled "Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol". The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of ra...
What is the current status of trial NCT00325767?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2004-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00325767?
The interventions under investigation include: nebulized albuterol (2.5 mg/3ml/dose) (DRUG), nebulized levalbuterol (1.25 mg/3ml/dose) (DRUG), nebulized placebo (3ml/dose) (DRUG).
Who is sponsoring clinical trial NCT00325767?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.